The presence of large numbers of introns in genes was a driving force in the evolution of complex organisms, because it allowed variation in the way exons were joined together to form mRNA. But the ...

What's the difference between mRNA and pre-mRNA? It's all about splicing of introns. See how one RNA sequence can exist in nearly 40,000 different forms. Next, the snRNPs U2 and U4/U6 appear to ...

Researchers at the Center for Genomic Regulation (CRG) in Barcelona have created the first blueprint of the human spliceosome ...

A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed into mRNA precursors, is correctly assembled into mature mRNA. Splicing is a ...

In human cells, only a small proportion of the information written in genes is used to produce proteins. How does the cell select this information? A large molecular machine called the spliceosome ...

Watching fruit flies buzz around the ripe bananas in your kitchen, you might think it’s a tad ludicrous, mortifying even, that humans have a similar number of genes—about 23,000—as the lowly insects.

Certain diseases such as cystic fibrosis and muscular dystrophy are linked to genetic mutations that damage the important biological process of rearranging gene sequences in pre-messenger RNA, a ...

Researchers have created the first blueprint of the human spliceosome, the most complex and intricate molecular machine in human biology. The vast majority of human genes -- more than nine in ten -- ...

Two molecular control factors play a decisive role in what is known as splicing, the cutting and assembly of mature messenger RNA—a prerequisite for protein synthesis in the cell. The poorly ...

Researchers at the Centre for Genomic Regulation (CRG) have created the first blueprint of the human spliceosome, the complex molecular machine that edits genetic messages transcribed from DNA, ...

BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...

BOSTON and LONDON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...